BACKGROUND: Although various injected peptide and protein therapeutics have been developed successfully over the past 25 years, several pharmacokinetic and immunological challenges are still encountered that can limit the efficacy of both novel and established biotech molecules. OBJECTIVE AND METHOD: PEGylation is a popular technique to address such properties. PEGylated drugs exhibit prolonged half-life, higher stability, water solubility, lower immunogenicity and antigenicity, as well as potential for specific cell targeting. Although PEGylated drug conjugates have been on the market for many years, the technology has steadily developed in respect of site-specific chemistry, chain length, molecular weights and purity of conjugate. These developments have occurred in parallel to improvements in physicochemical methods of characterization. CONCLUSION: This review will discuss recent achievements in PEGylation processes with an emphasis on novel PEG-drugs constructs, the unrealized potential of PEGylation for non-injected routes of delivery, and also on PEGylated versions of polymeric nanoparticles, including dendrimers and liposomes.
BACKGROUND: Although various injected peptide and protein therapeutics have been developed successfully over the past 25 years, several pharmacokinetic and immunological challenges are still encountered that can limit the efficacy of both novel and established biotech molecules. OBJECTIVE AND METHOD: PEGylation is a popular technique to address such properties. PEGylated drugs exhibit prolonged half-life, higher stability, water solubility, lower immunogenicity and antigenicity, as well as potential for specific cell targeting. Although PEGylated drug conjugates have been on the market for many years, the technology has steadily developed in respect of site-specific chemistry, chain length, molecular weights and purity of conjugate. These developments have occurred in parallel to improvements in physicochemical methods of characterization. CONCLUSION: This review will discuss recent achievements in PEGylation processes with an emphasis on novel PEG-drugs constructs, the unrealized potential of PEGylation for non-injected routes of delivery, and also on PEGylated versions of polymeric nanoparticles, including dendrimers and liposomes.
Authors: Haiming Ding; Michelle M Carlton; Stephen P Povoski; Keisha Milum; Krishan Kumar; Shankaran Kothandaraman; George H Hinkle; David Colcher; Rich Brody; Paul D Davis; Alex Pokora; Mitchell Phelps; Edward W Martin; Michael F Tweedle Journal: Bioconjug Chem Date: 2013-10-31 Impact factor: 4.774
Authors: Ben-Quan Shen; Keyang Xu; Luna Liu; Helga Raab; Sunil Bhakta; Margaret Kenrick; Kathryn L Parsons-Reponte; Janet Tien; Shang-Fan Yu; Elaine Mai; Dongwei Li; Jay Tibbitts; Jakub Baudys; Ola M Saad; Suzie J Scales; Paul J McDonald; Philip E Hass; Charles Eigenbrot; Trung Nguyen; Willy A Solis; Reina N Fuji; Kelly M Flagella; Darshana Patel; Susan D Spencer; Leslie A Khawli; Allen Ebens; Wai Lee Wong; Richard Vandlen; Surinder Kaur; Mark X Sliwkowski; Richard H Scheller; Paul Polakis; Jagath R Junutula Journal: Nat Biotechnol Date: 2012-01-22 Impact factor: 54.908
Authors: Widya Mulyasasmita; Lei Cai; Ruby E Dewi; Arshi Jha; Sabrina D Ullmann; Richard H Luong; Ngan F Huang; Sarah C Heilshorn Journal: J Control Release Date: 2014-05-18 Impact factor: 9.776
Authors: Jiaojie Tan; Tae Joon Cho; De-Hao Tsai; Jingyu Liu; John M Pettibone; Rian You; Vincent A Hackley; Michael R Zachariah Journal: Langmuir Date: 2017-12-18 Impact factor: 3.882
Authors: Sjoerd Hak; Zuzana Garaiova; Linda Therese Olsen; Asbjørn Magne Nilsen; Catharina de Lange Davies Journal: Pharm Res Date: 2014-10-28 Impact factor: 4.200